FDAnews
www.fdanews.com/articles/84743-dmc-recommends-continuation-of-ferumoxytol-studies

DMC RECOMMENDS CONTINUATION OF FERUMOXYTOL STUDIES

February 21, 2006

Advanced Magnetics today announced that the independent data monitoring committee (DMC) providing oversight for the ferumoxytol Phase III iron replacement therapy program has informed the company that it has reviewed the cumulative safety data from the ferumoxytol Phase III studies and identified no safety concerns. The DMC also recommended the continuation of the ferumoxytol Phase III studies.

Ferumoxytol, the key product in the company's development pipeline, is in Phase III multicenter clinical trials for use as an intravenous iron replacement therapeutic in chronic kidney disease patients, whether or not on dialysis.